Stocksigma LogoStocksigma Logo

Goldline Pharmaceutical H1 FY27 Net Profit Rises 44.5% YoY to Rs 205.15 Lakh

Goldline Pharmaceutical reported standalone revenue from operations of Rs 1,492.50 lakh for the half year ended 30th Sep'26, up 7.4% YoY from Rs 1,389.21

Goldline Pharmaceutical H1 FY27 Net Profit Rises 44.5% YoY to Rs 205.15 Lakh

Goldline Pharmaceutical Ltd 路 Outcome 路 15 Nov 2026, 1:03 am

Goldline Pharmaceutical H1 FY27 Net Profit Rises 44.5% YoY to Rs 205.15 Lakh Goldline Pharmaceutical reported standalone revenue from operations of Rs 1,492.50 lakh for the half year ended 30th Sep'26, up 7.4% YoY from Rs 1,389.21 lakh in H1 FY26. Profit before tax rose 25.1% YoY to Rs 231.51 lakh compared to Rs 185.09 lakh. Net profit surged 44.5% YoY to Rs 205.15 lakh versus Rs 141.96 lakh, while basic and diluted EPS expanded to Rs 2.31 from Rs 1.96. Net cash flow from operating activities stood at Rs 10.93 lakh, with total cash and cash equivalents ending at Rs 155.52 lakh.

Original exchange filing (PDF)

More announcements from Goldline Pharmaceutical Ltd

All Goldline Pharmaceutical Ltd announcements